Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy

Anti-Cancer Drugs

Volumn 18, Issue 7, 2007, Pages 817-820

  Petrioli, Roberto ^a   Paolelli, Loretta ^a   Francini, Edoardo ^a   Marsili, Stefania ^a   Pascucci, Alessandra ^a   Sciandivasci, Angela ^a   De Rubertis, Giovanni ^a   Barbanti, Gabriele ^a   Manganelli, Antonio ^a   Salvestrini, Francesco ^a   Francini, Guido ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Capecitabine; Interferon; Interleukin 2; Renal carcinoma; Third line

Indexed keywords

ALPHA INTERFERON; CAPECITABINE; DOXORUBICIN; FLUOROURACIL; INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; FEMALE; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; MALE; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUTROPENIA; PRIORITY JOURNAL; REMISSION; STOMATITIS; THIRD LINE TREATMENT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PRODRUGS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT FAILURE;

EID: 34250874424     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280a02f17     Document Type: Article

References (24)

1. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22:42-60.
2. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. Group Francais d'Immunotherapie. N Engl J Med 1998; 338:1272-1278.
3. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006; 94:614-619.
4. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al. Sorafenib for the treatment of renal cell carcinoma. Clin Cancer Res 2006; 12:7271-7278.
5. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon-alfa in metastatic renal cell carcinoma (mRCC). N Engl J Med 2007; 356:115-124.
7. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004; 101:1545-1551.
8. Atzpodien J, Kirchner H, Lopez-Hanninen E, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993; 29A (Suppl 5):S6-S8.
9. Allen MJ, Vaughan M, Webb A, Johnston S, Savage P, Eisen T, et al. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer 2000; 83:980-985.
10. Rini BI, Vogelzanq NJ, Dumas MC, Wade JL, 3rd, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. J Clin Oncol 2000; 18:2419-2426.
11. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485-493.
12. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-4106.
13. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58:685-690.
14. Amato RJ, Rawat A. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study. Invest New Drugs 2006; 24:171-175.
15. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evacuate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-261.
16. Glaspy JA. Therapeutic options in the management of renal cell carcinoma. Semin Oncol 2002; 29 (3 Suppl 7):41-46.
17. Hartmann JT, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 1999; 19:1541-1543.
18. Wenzel C, Locker GJ, Schmidinger M, Mader R, Kramer G, Marberger M, et al. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney Dis 2002; 39:48-54.
19. Oevermann K, Buer J, Hoffmann R, Franzke A, Schrader A, Patzelt T, et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 2000; 83:583-587.
20. Padrik P, Leppik K, Arak A. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study. Urol Oncol 2004; 22:387-392.
21. Chang DZ, Olencki T, Budd T, Peereboom D, Ganapathi R, Osterwalder B, et al. Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics. Cancer Chemother Pharmacol 2001; 48:493-498.
22. Waters JS, Moss C, Pyle L, James M, Hackett S, A'hern R, et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004; 91:1763-1768.
23. Rini BI,Weinberg V, Small EJ. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer 2005; 103:553-558.
24. Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 2006; 107:1273-1279.